IBDEI120 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18581,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18581,1,4,0)
 ;;=4^WISKOTT-ALDRICH SYNDROME
 ;;^UTILITY(U,$J,358.3,18581,1,5,0)
 ;;=5^279.12
 ;;^UTILITY(U,$J,358.3,18581,2)
 ;;=^127982
 ;;^UTILITY(U,$J,358.3,18582,0)
 ;;=277.00^^102^1193^3
 ;;^UTILITY(U,$J,358.3,18582,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18582,1,4,0)
 ;;=4^CYSTIC FIBROS W/O ILEUS
 ;;^UTILITY(U,$J,358.3,18582,1,5,0)
 ;;=5^277.00
 ;;^UTILITY(U,$J,358.3,18582,2)
 ;;=^30278
 ;;^UTILITY(U,$J,358.3,18583,0)
 ;;=277.01^^102^1193^2
 ;;^UTILITY(U,$J,358.3,18583,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18583,1,4,0)
 ;;=4^CYST FIBR W MECONIUM ILEUS
 ;;^UTILITY(U,$J,358.3,18583,1,5,0)
 ;;=5^277.01
 ;;^UTILITY(U,$J,358.3,18583,2)
 ;;=^267951
 ;;^UTILITY(U,$J,358.3,18584,0)
 ;;=277.6^^102^1193^4
 ;;^UTILITY(U,$J,358.3,18584,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18584,1,4,0)
 ;;=4^DEFIC CIRCUL ENZYME NEC
 ;;^UTILITY(U,$J,358.3,18584,1,5,0)
 ;;=5^277.6
 ;;^UTILITY(U,$J,358.3,18584,2)
 ;;=^87463
 ;;^UTILITY(U,$J,358.3,18585,0)
 ;;=277.82^^102^1193^1
 ;;^UTILITY(U,$J,358.3,18585,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18585,1,4,0)
 ;;=4^CRNITNE DEF D/T NB MET
 ;;^UTILITY(U,$J,358.3,18585,1,5,0)
 ;;=5^277.82
 ;;^UTILITY(U,$J,358.3,18585,2)
 ;;=^329882
 ;;^UTILITY(U,$J,358.3,18586,0)
 ;;=277.83^^102^1193^7
 ;;^UTILITY(U,$J,358.3,18586,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18586,1,4,0)
 ;;=4^IATROGENIC CARNITINE DEF
 ;;^UTILITY(U,$J,358.3,18586,1,5,0)
 ;;=5^277.83
 ;;^UTILITY(U,$J,358.3,18586,2)
 ;;=^329883
 ;;^UTILITY(U,$J,358.3,18587,0)
 ;;=277.84^^102^1193^9
 ;;^UTILITY(U,$J,358.3,18587,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18587,1,4,0)
 ;;=4^SEC CARNITINE DEFNCY NEC
 ;;^UTILITY(U,$J,358.3,18587,1,5,0)
 ;;=5^277.84
 ;;^UTILITY(U,$J,358.3,18587,2)
 ;;=^329884
 ;;^UTILITY(U,$J,358.3,18588,0)
 ;;=277.85^^102^1193^6
 ;;^UTILITY(U,$J,358.3,18588,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18588,1,4,0)
 ;;=4^DISORDERS ACID OXIDATION
 ;;^UTILITY(U,$J,358.3,18588,1,5,0)
 ;;=5^277.85
 ;;^UTILITY(U,$J,358.3,18588,2)
 ;;=^331443
 ;;^UTILITY(U,$J,358.3,18589,0)
 ;;=277.86^^102^1193^8
 ;;^UTILITY(U,$J,358.3,18589,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18589,1,4,0)
 ;;=4^PEROXISOMAL DISORDERS
 ;;^UTILITY(U,$J,358.3,18589,1,5,0)
 ;;=5^277.86
 ;;^UTILITY(U,$J,358.3,18589,2)
 ;;=^331444
 ;;^UTILITY(U,$J,358.3,18590,0)
 ;;=277.87^^102^1193^5
 ;;^UTILITY(U,$J,358.3,18590,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18590,1,4,0)
 ;;=4^DIS MITOCHONDRIAL METAB
 ;;^UTILITY(U,$J,358.3,18590,1,5,0)
 ;;=5^277.87
 ;;^UTILITY(U,$J,358.3,18590,2)
 ;;=^331445
 ;;^UTILITY(U,$J,358.3,18591,0)
 ;;=277.88^^102^1193^10
 ;;^UTILITY(U,$J,358.3,18591,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18591,1,4,0)
 ;;=4^TUMOR LYSIS SYNDROME
 ;;^UTILITY(U,$J,358.3,18591,1,5,0)
 ;;=5^277.88
 ;;^UTILITY(U,$J,358.3,18591,2)
 ;;=^338229
 ;;^UTILITY(U,$J,358.3,18592,0)
 ;;=V42.0^^102^1194^7
 ;;^UTILITY(U,$J,358.3,18592,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18592,1,4,0)
 ;;=4^KIDNEY TRANSPLANT STATUS
 ;;^UTILITY(U,$J,358.3,18592,1,5,0)
 ;;=5^V42.0
 ;;^UTILITY(U,$J,358.3,18592,2)
 ;;=^121356
 ;;^UTILITY(U,$J,358.3,18593,0)
 ;;=V42.1^^102^1194^4
 ;;^UTILITY(U,$J,358.3,18593,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18593,1,4,0)
 ;;=4^HEART TRANSPLANT STATUS
 ;;^UTILITY(U,$J,358.3,18593,1,5,0)
 ;;=5^V42.1
 ;;^UTILITY(U,$J,358.3,18593,2)
 ;;=^54832
 ;;^UTILITY(U,$J,358.3,18594,0)
 ;;=V42.2^^102^1194^5
 ;;^UTILITY(U,$J,358.3,18594,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18594,1,4,0)
 ;;=4^HEART VALVE TRANSPLANT
 ;;^UTILITY(U,$J,358.3,18594,1,5,0)
 ;;=5^V42.2
 ;;
 ;;$END ROU IBDEI120
